Inovio Pharmaceuticals Inc <INO.OQ> expected to post a loss of 84 cents a share - Earnings Preview
Inovio Pharmaceuticals Inc INO.OQ INO.O is expected to show a fall in quarterly revenue when it reports results on March 18 for the period ending December 31 2024
The Plymouth Meeting Pennsylvania-based company is expected to report a 70.8% decrease in revenue to $30 thousand from $102.65 thousand a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Inovio Pharmaceuticals Inc is for a loss of 84 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Inovio Pharmaceuticals Inc is $8.00, above its last closing price of $1.93.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2024 | -1.14 | -1.15 | -0.89 | Beat | 22.6 |
Jun. 30 2024 | -1.12 | -1.10 | -1.19 | Missed | -8 |
Mar. 31 2024 | -1.01 | -1.00 | -1.31 | Missed | -30.6 |
Dec. 31 2023 | -1.42 | -1.27 | -1.12 | Beat | 11.6 |
Sep. 30 2023 | -1.50 | -1.52 | -1.56 | Missed | -2.6 |
Jun. 30 2023 | -1.81 | -1.74 | -1.56 | Beat | 10.3 |
Mar. 31 2023 | -1.76 | -1.74 | -1.92 | Missed | -10.3 |
Dec. 31 2022 | -2.01 | -2.02 | -2.52 | Missed | -25 |
This summary was machine generated March 14 at 20:22 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
